Author

Marie-Pascale Graas

Observed names: M P Graas, M-PL Graas, M.P. Graas, MARIE-PASCALE GRAAS, Marie-Pascale GRAAS, Marie-Pascale L. Graas

Observed institutions: Memorial Sloan Kettering Cancer Center, Instituto Português de Oncologia de Coimbra Francisco Gentil, Paracelsus Medical University, Kaplan Medical Center, University Hospital of Bern, Ghent University Hospital, Rambam Health Care Campus, Groupe santé CHC, Hospital Universitario 12 De Octubre, Instituto Português de Oncologia Francisco Gentil, Assaf Harofeh Medical Center, Clinique Saint-Joseph, REseau NAtional de Rpe interDisciplinaire, Damiaan Dicht bij het leven, AZ Turnhout, Centre Hospitalier Universitaire de Liège, International Breast Cancer Study Group, Vall d'Hebron Institute of Oncology

OpenAlex ID: A5032818174

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

2013 · José Baselga, Patricia Gómez, et al. · Journal of Clinical Oncology · 368

PDF

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

2017 · Marco Colleoni, Weixiu Luo, et al. · The Lancet Oncology · 121

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

2019 · Ignace Vergote, Giovanni Scambia, et al. · The Lancet Oncology · 91

PDF

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma

2015 · Jacques De Grève, Teresa Moran, et al. · Lung Cancer · 91

Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

2020 · Hannelore Denys, Corina L. Martinez-Mena, et al. · Breast Cancer Research and Treatment · 44

PDF

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

2021 · Andrew Wardley, Javier Cortes, et al. · Breast Cancer Research and Treatment · 32

PDF

Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy

2021 · G. Jerusalem, S. Farah, et al. · Annals of Oncology · 30

Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases

2022 · Debu Tripathy, Sara M. Tolaney, et al. · JAMA Oncology · 25

Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer

2016 · Weimin Li, Joyce O'Shaughnessy, et al. · Clinical Cancer Research · 24

Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial

2025 · Etienne Brain, Olivier Mir, et al. · The Lancet · 22

Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial

2020 · Elena Guerini-Rocco, Kathryn P. Gray, et al. · Clinical Cancer Research · 11

PDF

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

2019 · on behalf of the SOLE Investigators, Karin Ribi, et al. · British Journal of Cancer · 10

PDF

Dietetic and Psychological Mindfulness Workshops for the Management of Cachectic Cancer Patients. A Randomized Study.

2015 · Christian Focan, Ghislain Houbiers, et al. · PubMed · 10

SOLE (Study of Letrozole Extension): A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC).

2017 · Marco Colleoni, Weixiu Luo, et al. · Journal of Clinical Oncology · 9

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined non-small cell lung cancer (NSCLC) patients.

2013 · Jacques De Greve, Teresa Moran, et al. · Journal of Clinical Oncology · 9

Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group

2022 · Ignace Vergote, Els Van Nieuwenhuysen, et al. · International Journal of Gynecological Cancer · 7

PDF

Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial.

2005 · C Focan, M P Graas, et al. · PubMed · 6

Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

2020 · Karin Ribi, Weixiu Luo, et al. · British Journal of Cancer · 5

PDF

Effect of lipegfilgrastim administration as prophylaxis of chemotherapy-induced neutropenia on dose modification and incidence of neutropenic events: real-world evidence from a non-interventional study in Belgium and Luxembourg

2019 · Christel Fontaine, Nele Claes, et al. · Acta Clinica Belgica · 5

Abstract P4-21-17: BELIS: Safety and tolerability of at home administration of trastuzumab (Herceptin®) subcutaneous for the treatment of patients with HER2-positive early breast cancer

2017 · VF Cocquyt, CL Martinez-Mena, et al. · Cancer Research · 4

Interest for a Systematic Rehabilitation Program Including Physical Exercise and Lifestyle Accompaniment for Women Recently Treated for Early Breast Cancer: A Comparative Study

2020 · STEPHANIE MARECHAL, MARIE-PASCALE GRAAS, et al. · Anticancer Research · 3

PDF

The Sentinel Lymph Node Biopsy in Breast Cancer

2002 · J.M. Weerts, S. Maweja, et al. · Acta chirurgica Belgica · 2

Integration of Chronobiological Concepts for NSCLC Management

2019 · Christian Focan, Anne-Catherine Davin, et al. · IntechOpen eBooks · 1

PDF

Evaluation of biomarker association with efficacy for abiraterone acetate (AA) plus prednisone (P) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (mBCa) progressing after a nonsteroidal aromatase inhibitor (NSAI).

2014 · Weimin Li, Joyce O'Shaughnessy, et al. · Journal of Clinical Oncology · 1

[A trans-hospital pilot programme for onco-geriatry. The experience of the CHC-Liege].

2013 · C Focan, E Warzee, et al. · PubMed · 1

Works count: 47

Citation count: 932

H-index: 11

I10-index: 13